Johnson & Johnson $JNJ reported sales of $17.82 billion for the fiscal Q3 of 2016, an increase of 4.2%, year-over-year, beating analysts� consensus estimate by $110 million. Operational sales climbed 4.3% and the negative impact of currency was 0.1%. Domestic sales rose 6.7%. International sales increased 1.5%. EPS stood at $1.68, bettering Wall Street�s consensus estimates by $0.03. For the fiscal 2016, revenue is expected between $71.5 billion and $72.2 billion. Non-GAAP EPS was upwardly revised to $6.68-$6.73 from $6.63 and $6.73.